Key result
Antiplatelet therapy, particularly fixed-dose oral formulations, plays a fundamental role in preventing atherothrombotic events and managing established ischemic disease.
This review discusses the evidence for antiplatelet therapy in preventing atherothrombotic events, emphasizing the use of fixed-dose oral formulations to improve adherence in patients requiring dual antiplatelet therapy.
Supports antiplatelet emphasis for adherence in ischemic disease; leaves open prospective validation of optimal regimens.
Antiplatelet therapy plays a fundamental role in reducing atherothrombotic events by several pathways. The present work reviews available evidence on antiplatelet therapy both for primary prevention and in the presence of established peripheral, cerebral, or cardiac ischemic disease. Due to the importance of adherence to therapy to achieve optimal effects, special attention is given to the use of fixed-dose oral formulations in the clinical subset of patients in whom double antiplatelet therapy has proven indications.
No takes yet. Share an insight, caveat, or question.
Anselmino et al. (2011) conducted a review in Atherothrombotic events. Antiplatelet therapy was evaluated. Antiplatelet therapy, particularly fixed-dose oral formulations, plays a fundamental role in preventing atherothrombotic events and managing established ischemic disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: